4547:TYO
Kissei Pharmaceutical Co Ltd
JP¥3,790.00
arrow_upward
+0.53%(+20.00) 1D
ኖቬም 12, 9:22:55 ጥዋት ጂ ኤም ቲ+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
JP¥3,790
High
JP¥3,830
Low
JP¥3,790
Mkt. cap
176.39 ቢ
Avg. vol.
87.26 ሺ
Volume
17.20 ሺ
Dividend
3.30%
Quarterly dividend
JP¥31
Ex-dividend date
29 ሴፕቴ 2026
P/E ratio
14.05
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
Open
JP¥3,790
High
JP¥3,830
Low
JP¥3,790
Mkt. cap
176.39 ቢ
Avg. vol.
87.26 ሺ
Volume
17.20 ሺ
Dividend
3.30%
Quarterly dividend
JP¥31
Ex-dividend date
29 ሴፕቴ 2026
P/E ratio
14.05
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
News stories
From web sources and news partners
Eurasia Business News
·
ከ4 ሰዓቶች በፊት
Stock Market Today: Dow Jones, Nasdaq, S&P 500 Rally on November 11, 2026; Oil Rises, Gold Slips
ChartMill
·
ከ2 ሰዓቶች በፊት
S&P 500 After-Hours Movers: MNST, RDDT Among Gainers; VEEV, LLY Among Losers in Latest Session
marketscreener.com
·
ከ4 ሰዓቶች በፊት
S&P 500's Earnings Growth to Slow in 2027, 2028, UBS Says
Traders Union
·
ከ2 ሰዓቶች በፊት
Peter Tuchman: S&P 500 gains over $900 billion in market cap, closing up 1.3 percent
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79 ሺ
Founded9 ኦገስ 1946
HeadquartersMatsumoto, Nagano, ጃፓን
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp